||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 666 active entries
6100, avenue Royalmount
Montreal, QC, H4P 2R2
REPLICor is a biopharmaceutical company developing a new antiviral drug that will revolutionize the treatment of patients with chronic hepatitis B and for patients with hepatitis D. This antiviral drug is currently being tested in clinical trials in Asia and Moldova to demonstrate its safety and activity in human patients. It is expected that our drug will also find important applications in the treatment of patients infected with influenza, RSV and CMV.
Last update of this entry: September 06, 2016
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking